Targeting Integrins for Cancer Therapy - Disappointments and Opportunities
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Integrins for Cancer Therapy - Disappointments and Opportunities
Authors
Keywords
-
Journal
Frontiers in Cell and Developmental Biology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-03-09
DOI
10.3389/fcell.2022.863850
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Integrin αvβ6–TGFβ–SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer
- (2021) Archis Bagati et al. CANCER CELL
- Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions
- (2021) Francesco Pantano et al. ONCOGENE
- Differential expression of αVβ3 and αVβ6 integrins in prostate cancer progression
- (2021) Fabio Quaglia et al. PLoS One
- Molecular Delivery of Cytotoxic Agents via Integrin Activation
- (2021) Martina Cirillo et al. Cancers
- Integrin β5 enhances the malignancy of human colorectal cancer by increasing the TGF-β signaling
- (2021) Wei Shi et al. ANTI-CANCER DRUGS
- ITGA5 is a prognostic biomarker and correlated with immune infiltration in gastrointestinal tumors
- (2021) Hai Zhu et al. BMC CANCER
- Integrin αvβ3-targeted liposomal drug delivery system for enhanced lung cancer therapy
- (2021) Shuang Fu et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Integrins as attractive targets for cancer therapeutics
- (2021) Meng Li et al. Acta Pharmaceutica Sinica B
- Tumor acidic microenvironment-induced drug release of RGD peptide nanoparticles for cellular uptake and cancer therapy
- (2021) Zhongying Gong et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Biphasic α2β1 Integrin Expression in Breast Cancer Metastasis to Bone
- (2021) Milene N.O. Moritz et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress).
- (2021) Amita Patnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated single institution outcome data from the first-in-human CEND-1 trial in metastatic pancreatic cancer.
- (2021) Andrew Peter Dean et al. JOURNAL OF CLINICAL ONCOLOGY
- Cationic Liposome Decorated with Cyclic RGD Peptide for Targeted Delivery of anti-STAT3 siRNA to Melanoma Cancer Cells
- (2021) Ehsan Khabazian et al. JOURNAL OF DRUG TARGETING
- Integrin α2β1 Targeting DGEA-Modified Liposomal Doxorubicin Enhances Antitumor Efficacy against Breast Cancer
- (2021) Bingjie Zhou et al. MOLECULAR PHARMACEUTICS
- Emerging therapeutic opportunities for integrin inhibitors
- (2021) R. J. Slack et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting cancer stem cells via integrin β4
- (2021) Hannah E. Dobson et al. Oncotarget
- Integrin αvβ8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy
- (2021) Eswari Dodagatta-Marri et al. Cell Reports
- β6-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma
- (2021) Daniela Lenggenhager et al. Clinical and Translational Gastroenterology
- Integrin αvβ3-targeted polydopamine-coated gold nanostars for photothermal ablation therapy of hepatocellular carcinoma
- (2021) Yang Li et al. Regenerative Biomaterials
- Comparison of Linear vs. Cyclic RGD Pentapeptide Interactions with Integrin αvβ3 by Molecular Dynamics Simulations
- (2021) Na Li et al. Biology-Basel
- Primary tumors release ITGBL1-rich extracellular vesicles to promote distal metastatic tumor growth through fibroblast-niche formation
- (2020) Qing Ji et al. Nature Communications
- The exosomal integrin α5β1/AEP complex derived from epithelial ovarian cancer cells promotes peritoneal metastasis through regulating mesothelial cell proliferation and migration
- (2020) Xiaoduan Li et al. CELLULAR ONCOLOGY
- Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
- (2020) Shuhong Shen et al. JAMA Oncology
- Chapter 22: Structural and signaling functions of integrins
- (2020) Yasmin A. Kadry et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- The force awakens: metastatic dormant cancer cells
- (2020) So-Yeon Park et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials
- (2020) Atish Mohanty et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far
- (2020) Stefano Martellucci et al. Cancers
- 1528P Phase I trial of the first-in-class agent CEND-1 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer
- (2020) A. Dean et al. ANNALS OF ONCOLOGY
- Concepts of extracellular matrix remodelling in tumour progression and metastasis
- (2020) Juliane Winkler et al. Nature Communications
- Metastasis: crosstalk between tissue mechanics and tumour cell plasticity
- (2020) Bircan Coban et al. BRITISH JOURNAL OF CANCER
- Thermosensitive and biodegradable hydrogel encapsulating targeted nanoparticles for the sustained co-delivery of gemcitabine and paclitaxel to pancreatic cancer cells
- (2020) Ahmed M. Shabana et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- The Roles of Integrin α5β1 in Human Cancer
- (2020) Jianbing Hou et al. OncoTargets and Therapy
- Convection-Enhanced Delivery of a First-in-Class Anti-β1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging
- (2020) Chibueze D. Nwagwu et al. Pharmaceutics
- Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance
- (2019) Jonathan Cooper et al. CANCER CELL
- Integrins as biomechanical sensors of the microenvironment
- (2019) Jenny Z. Kechagia et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Are Integrins Still Practicable Targets for Anti-Cancer Therapy?
- (2019) Alday-Parejo et al. Cancers
- Cell Adhesion by Integrins
- (2019) Michael Bachmann et al. PHYSIOLOGICAL REVIEWS
- Integrin Beta 5 Is a Prognostic Biomarker and Potential Therapeutic Target in Glioblastoma
- (2019) Lu-yang Zhang et al. Frontiers in Oncology
- The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer
- (2019) Ru Wang et al. BMC CANCER
- Integrin-β5, a miR-185-targeted gene, promotes hepatocellular carcinoma tumorigenesis by regulating β-catenin stability
- (2018) Zhikun Lin et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Prostate cancer sheds the αvβ3 integrin in vivo through exosomes
- (2018) Shiv Ram Krishn et al. MATRIX BIOLOGY
- 487PPatient selection for targeting integrin with abituzumab in patients with metastatic colorectal cancer (mCRC): A retrospective analysis of the randomized phase I/II Poseidon study
- (2018) R Laeufle et al. ANNALS OF ONCOLOGY
- Integrin activation by talin, kindlin and mechanical forces
- (2018) Zhiqi Sun et al. NATURE CELL BIOLOGY
- Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer
- (2017) Rehman Ata et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Integrins as Therapeutic Targets: Successes and Cancers
- (2017) Sabine Raab-Westphal et al. Cancers
- Advancement in integrin facilitated drug delivery
- (2016) Daniela Arosio et al. ADVANCED DRUG DELIVERY REVIEWS
- Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis
- (2016) Annette Becker et al. CANCER CELL
- Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2016) M. Hussain et al. CLINICAL CANCER RESEARCH
- Integrin antagonists as potential therapeutic options for the treatment of Crohn’s disease
- (2016) Leon P. McLean et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Exosome-mediated Transfer of v 3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype
- (2016) A. Singh et al. MOLECULAR CANCER RESEARCH
- Integrin-based therapeutics: biological basis, clinical use and new drugs
- (2016) Klaus Ley et al. NATURE REVIEWS DRUG DISCOVERY
- Rational design of a protein that binds integrin αvβ3 outside the ligand binding site
- (2016) Ravi Chakra Turaga et al. Nature Communications
- Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)
- (2015) J. Vansteenkiste et al. ANNALS OF ONCOLOGY
- The αvβ6Integrin Is Transferred Intercellularly via Exosomes
- (2015) Carmine Fedele et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tumour exosome integrins determine organotropic metastasis
- (2015) Ayuko Hoshino et al. NATURE
- Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)
- (2015) Andrew B. Lassman et al. NEURO-ONCOLOGY
- Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance
- (2015) Laetitia Seguin et al. TRENDS IN CELL BIOLOGY
- Integrin β6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC)
- (2015) Zequn Li et al. TUMOR BIOLOGY
- Integrin activation
- (2015) Mark H. Ginsberg BMB Reports
- Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients withKRASwild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
- (2014) E. Élez et al. ANNALS OF ONCOLOGY
- Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)
- (2014) J. B. Vermorken et al. ANNALS OF ONCOLOGY
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
- (2014) Roger Stupp et al. LANCET ONCOLOGY
- 1 Integrin Inhibition Elicits a Prometastatic Switch Through the TGF -miR-200-ZEB Network in E-Cadherin-Positive Triple-Negative Breast Cancer
- (2014) H. H. Truong et al. Science Signaling
- Regulated Splicing of the α6 Integrin Cytoplasmic Domain Determines the Fate of Breast Cancer Stem Cells
- (2014) Hira Lal Goel et al. Cell Reports
- How Natalizumab Binds and Antagonizes α4Integrins
- (2013) Yamei Yu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Liposomal drug delivery systems: From concept to clinical applications
- (2012) Theresa M. Allen et al. ADVANCED DRUG DELIVERY REVIEWS
- A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer
- (2012) A. Heidenreich et al. ANNALS OF ONCOLOGY
- Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer
- (2012) B. Besse et al. ANNALS OF ONCOLOGY
- Extracellular matrix, integrins, and growth factors as tailors of the stem cell niche
- (2012) Maria Felice Brizzi et al. CURRENT OPINION IN CELL BIOLOGY
- Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways
- (2012) A Bianchi-Smiraglia et al. ONCOGENE
- Integrins as therapeutic targets
- (2012) Simon L. Goodman et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- β1 integrin deletion enhances progression of prostate cancer in the TRAMP mouse model
- (2012) Kim Moran-Jones et al. Scientific Reports
- Natalizumab
- (2012) Richard Rudick et al. JAMA Neurology
- Cooperation Between Integrins and Growth Factor Receptors in Signaling and Endocytosis
- (2011) Johanna Ivaska et al. Annual Review of Cell and Developmental Biology
- A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma
- (2011) S O'Day et al. BRITISH JOURNAL OF CANCER
- Dasatinib combined with docetaxel for castration-resistant prostate cancer
- (2011) John C. Araujo et al. CANCER
- A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer
- (2011) Katherine M. Bell-McGuinn et al. GYNECOLOGIC ONCOLOGY
- Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
- (2011) Peter Carmeliet et al. NATURE REVIEWS DRUG DISCOVERY
- A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma
- (2010) Peter Hersey et al. CANCER
- Integrin–TGF-β crosstalk in fibrosis, cancer and wound healing
- (2010) Coert Margadant et al. EMBO REPORTS
- Extracellular matrix: A gatekeeper in the transition from dormancy to metastatic growth
- (2010) Dalit Barkan et al. EUROPEAN JOURNAL OF CANCER
- Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium
- (2010) Ajjai Alva et al. INVESTIGATIONAL NEW DRUGS
- The α2β1 integrin is a metastasis suppressor in mouse models and human cancer
- (2010) Norma E. Ramirez et al. JOURNAL OF CLINICAL INVESTIGATION
- Integrins
- (2009) Malgorzata Barczyk et al. CELL AND TISSUE RESEARCH
- Adhesion signaling - crosstalk between integrins, Src and Rho
- (2009) S. Huveneers et al. JOURNAL OF CELL SCIENCE
- The Extracellular Matrix: Not Just Pretty Fibrils
- (2009) R. O. Hynes SCIENCE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started